Companies › Portal Diabetes
1 active drug program in 1 registered trial: 1 Phase 1; Metabolic and endocrine.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Portal Insulin U-500 (PI-U500) Insulin analog | INS | Phase 1 | Type 1 Diabetes | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07341373 | Portal Insulin U-500 (PI-U500) | Phase 1 | Type 1 Diabetes | Metabolic and endocrine | Sep 2026 |
Elgan Pharma Gateway Institute for Brain Research Gan & Lee Pharmaceuticals.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.